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Abstract
Long non-coding RNAs (lncRNAs) are a large and diverse group of RNAs that are often lineage-
specific and that regulate multiple biological functions. Many are nuclear and are essential parts of 
ribonucleoprotein complexes that modify chromatin segments and establish active or repressive 
chromatin states; others are cytosolic and regulate the stability of mRNA or act as microRNA 
sponges. This Review summarizes the current knowledge of lncRNAs as regulators of the 
endocrine system, with a focus on the identification and mode of action of several endocrine-
important lncRNAs. We highlight lncRNAs that have a role in the development and function of 
pancreatic β cells, white and brown adipose tissue, and other endocrine organs, and discuss the 
involvement of these molecules in endocrine dysfunction (for example, diabetes mellitus). We 
also address the associations of lncRNAs with nuclear receptors involved in major hormonal 
signalling pathways, such as estrogen and androgen receptors, and the relevance of these 
associations in certain endocrine cancers.
Introduction
The traditional view of RNAs as merely message carriers from DNA to protein is fading. 
Pioneering conceptual work from several laboratories,1–4 together with early large-scale 
cloning undertakings such as FANTOM,5,6 revealed the existence of a large number of non-
coding transcripts, most of which were regarded as transcriptional noise. Simultaneously, 
technologic advances such as DNA tiling arrays,2,7 next-generation sequencing8 and the 
availability of human genome sequences,9,10 expressed sequence tags11 and large datasets of 
genomic functional elements from the ENCODE consortium12–16 have enabled a more 
refined view of mammalian transcriptomes. Now we understand that a substantial proportion 
of the genome is transcribed, but only a small fraction of DNA encodes proteins.2,17,18 The 
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non-protein-coding portion of the genome is transcribed to generate a vast array of non-
coding RNAs, which include (but are not limited to) transfer RNAs (tRNAs), ribosomal 
RNAs (rRNAs), small nucleolar RNAs (snoRNAs), microRNAs (miRNAs), long non-
coding RNAs (lncRNAs), small nuclear RNAs (snRNAs) and piwi-interacting RNAs 
(piRNAs).12,19 lncRNAs share many structural features with protein-coding mRNAs: 
lncRNAs are often transcribed by RNA polymerase II, are encoded by multiple exons and 
undergo canonical RNA splicing to yield RNA products that can be several kilobases in 
length.20 Mounting evidence is revealing regulatory roles for lncRNAs in governing gene 
expression during cellular development and homeostasis.21–24
In this Review, we summarize studies concerning the discovery and functions of lncRNAs 
in the endocrine system. As background information, we first describe the general features, 
functions and mechanisms of action of lncRNAs. Next, we discuss several studies from the 
past few years in which lncRNAs were identified in endocrine organs and their roles in the 
development and function of endocrine tissues were elucidated, as well as the potential links 
of lncRNAs to specific diseases such as diabetes mellitus and certain endocrine cancers.
General characteristics of lncRNAs
Definition
An operational definition of lncRNAs is that they are RNA transcripts longer than 200 bases 
and without evident protein-coding capacity. This definition is somewhat arbitrary, but this 
size cut-off can distinguish lncRNAs from many small RNAs, such as miRNAs, snRNAs, 
tRNAs, piRNAs and snoRNAs. The challenge in this definition is to test whether a transcript 
that apparently falls within this lncRNA classification can be translated into one or more 
small peptides. In early studies, the lack of coding potential was tested by analysing the 
degree of conservation of open reading frames across different species.25 New techniques 
such as ribosome footprint assays are being used to determine ribosome occupancy of 
specific RNAs and can be applied to determine if a lncRNA is being translated.26 However, 
some lncRNAs, such as H19, were observed to associate with ribosomes but no protein 
products were detected.25,26 Improved approaches are now being developed to accurately 
distinguish between real translation and non-productive ribosome occupancy.27–30
Categories
A detailed classification of lncRNAs can be very intricate. According to their relative 
genome position with respect to neighbouring protein-coding genes, lncRNAs can be 
categorized as antisense, intronic, intergenic, divergent and enhancer lncRNAs (Figure 1). 
Interestingly, numerous lncRNAs that are transcribed from enhancer regions (enhancer 
lncRNAs) mediate short-range and long-range interactions between the enhancers from 
which they are transcribed and other regulatory elements in the genome.31
According to their cellular localization, lncRNAs can be categorized as nuclear or cytosolic, 
but some lncRNAs can be found in both compartments. Nuclear lncRNAs such as Xist21are 
likely to exert their functions by modifying chromatin structure, thereby influencing gene 
transcription, whereas cytosolic lncRNAs regulate target mRNA stability and translational 
efficiency through RNA-RNA interactions (Figure 2). The observation that many nuclear 
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lncRNAs can be depleted in cultured cells by expression of short hairpin RNAs suggests that 
lncRNAs probably shuttle between the nucleus and cytosol, although this hypothesis has not 
been tested.13,32
Tissue specificity and conservation
lncRNAs have lower sequence conservation and abundance than mRNAs, properties which 
were once used to argue against any biological function for lncRNAs. However, a striking 
feature of lncRNAs is that, as a group, they have greater tissue specificity than protein-
coding RNAs,8,33 which suggests that lncRNAs might have a crucial role in the formation of 
multiple, if not all, cell types.
The primary sequence of lncRNAs is often poorly, if at all, conserved across species. A 
study of the evolution of lncRNAs in 11 tetrapods indicated that many lncRNAs in humans 
evolved very late and only a very small fraction of these lncRNAs, as judged by primary 
sequence similarity, have conserved orthologous genes beyond primates.34 However, this 
criterion might be less appropriate for assessing conservation of lncRNAs than of mRNAs, 
so some researchers have proposed that lncRNA conservation should be assessed on the 
basis of synteny of their gene loci and on the basis of their structure, rather than relying on 
sequence similarity.8,35 Indeed, lncRNAs derived from syntenic loci (lncRNAs whose 
chromosome position in relation to surrounding genes is the same) tend to have higher 
sequence similarity8,36 and more conserved functions37 than nonsyntenic lncRNAs. For 
example, knockdown of two zebrafish lncRNAs that have low sequence conservation in 
human and mouse caused major developmental defects in fish embryos; these defects were 
rescued by adding either the mature fish lncRNAs or their human or mouse orthologs that 
were identified by chromosome synteny.37 In addition, as lncRNAs are likely to function 
through the formation of secondary and tertiary structures, the major evolutionary constraint 
for lncRNAs could be to maintain their functional structures.38-40 However, accurate 
prediction of lncRNA structures still remains a big challenge for the field.
Mechanisms
In contrast to miRNAs, which exert their functions via an RNA-RNA base-pairing 
mechanism,41 lncRNAs act through diverse mechanisms that probably rely on their 
secondary or tertiary structures.42 Most lncRNAs are located in the nucleus,13,18 where they 
can act as molecular scaffolds,43 aid alternative splicing44 or modify chromatin structures 
(Figure 2).45-47 However, emerging evidence indicates that some lncRNAs, of which 
TINCR, ½-sbsRNA and ciRS-7 are examples, have functions in the cytoplasm, such as 
modulating translation, promoting or inhibiting mRNA degradation, and acting as miRNA 
sponges (which can be circular or linear molecules).24,48-51 As the lncRNA field moves 
forward, new perspectives on the mechanisms of lncRNA function will be seen in the near 
future.
Association with human disease
Genome-wide association studies (GWAS) have been used to identify associations between 
DNA sequence variation and clinical phenotypes. Since the first GWAS in 2005,52 hundreds 
of reports have been published, which identified thousands of single nucleotide 
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polymorphisms (SNPs) related to a variety of diseases including cancer, heart disease, 
neuron disorders, obesity and diabetes mellitus.53,54 However, most of these SNPs are found 
in non-coding regions, which poses an enigma for researchers attempting to connect 
functional DNA elements with diseases. The answer to this enigma lies, in part, in the 
comprehensive transcription process2,17,18,55 that produces thousands of species of non-
coding RNAs, including lncRNAs. Several studies have linked disease-associated SNPs to 
lncRNAs and documented these associations in multiple databases.56–59 In one study, the 
association of SNPs with the expression levels (assessed through analysis of expression 
quantitative trait loci, eQTLs) of large intergenic non-coding RNAs was investigated using 
genome-wide gene expression and genotype data from five different tissues.56 The 
researchers found that 75% of the SNPs affected expression of lncRNAs (lncRNA cis-
eQTLs) but not the neighbouring protein-coding genes. These results suggest a role of 
lncRNAs in human diseases.
lncRNAs in endocrine physiology and disease
Until just a few years ago, the roles of lncRNAs in endocrine physiology had not been 
examined and this field is still in its infancy. Very little knowledge exists on the function of 
lncRNAs in many important endocrine organs, including the pituitary, thyroid and 
parathyroid glands, and the hypothalamus. Studies from our laboratories and other groups, 
however, have revealed crucial roles of lncRNAs in the normal development and function of 
several other endocrine organs, as well as showing their involvement in endocrine diseases 
such as diabetes mellitus and endocrine cancers (Figure 3, Table 1). The number of 
functional lncRNAs identified in a variety of biological systems is increasing, and we 
anticipate a rapid expansion of knowledge about the involvement of lncRNAs in endocrine 
physiology and disease in the near future.
Glucose homeostasis and diabetes mellitus
In a first attempt to identify lncRNAs in the β-cell transcriptome of mice, the expression of 
1,359 potential lncRNAs was detected in mouse β cells; many of these lncRNAs are β-cell 
specific.53 At the same time, another group published a transcriptome analysis of human β 
cells and, through de novo assembly, identified 1,128 lncRNAs expressed in human 
pancreatic islets.60 Intriguingly, many of these lncRNA-encoding genes are located near 
genes encoding important regulators of β-cell function and the expression of some of these 
lncRNAs increased after addition of glucose to a β-cell culture, which suggested that these 
lncRNAs might be relevant for mature islet cell physiology. In an attempt to identify mouse 
counterparts of these lncRNAs, the researchers also analyzed mouse islet cells and tested 
whether the lncRNA orthologs are regulated in a similar manner. The investigators 
compared the expression pattern of eight mouse lncRNAs that were orthologous to human 
lncRNAs in the mouse embryonic pancreas at embryonic day 13.5 and in islet cells from 
adult mice. Five of the eight tested lncRNAs were not expressed in the embryonic pancreas 
but were expressed in the adult pancreas. This observation suggests that lncRNAs might be 
important for the development and cell identity of β cells in the adult pancreas. The 
researchers then focused on one of the identified lncRNAs, HI-LNC25, to determine its 
function. Knockdown of HI-LNC25 resulted in reduced mRNA levels of GLIS3, which 
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encodes an important islet transcription factor for which genetic variants associated with risk 
of type 2 diabetes mellitus (T2DM) are known.61–63 However, the underlying mechanisms 
by which HI-LNC25 functions remain to be elucidated.
In an effort to identify novel genes influencing glucose metabolism, microarray, RNA 
sequencing and exome sequencing methods were combined to analyse pancreatic islets from 
89 deceased individuals with or without T2DM.64 Besides the expression of many protein-
coding genes, the researchers identified 493 lncRNAs expressed in the pancreatic islets, of 
which 54 were involved in regulating gene expression and exon usage, as well as being 
correlated to the HbA1c levels of donors.64 This study provides a comprehensive catalog of 
gene regulation in human pancreatic β cells, including lncRNA expression, and offers 
insight into how genetic variation can influence glucose metabolism.64 Of note, seven of the 
54 lncRNAs identified in this study were also reported in one of the previous transcriptome 
analyses of human β cells of patients with T2DM.60
An imprinted lncRNA, H19, has also been shown to be involved in the intergenerational 
transmission of diabetes mellitus in a mouse model of gestational diabetes mellitus.65 The 
investigators showed that F2 offspring of mice with impaired glucose tolerance had 
increased risk of also developing impaired glucose tolerance through the paternal line that 
was accompanied by downregulated expression of Igf2 and H19 in pancreatic islets and 
abnormal DNA methylation status in differentially methylated regions in the Igf2–H19 
locus.65
Three GWAS revealed that the locus encoding the lncRNA ANRIL is associated with risk of 
T2DM.66-69 ANRIL is thought to associate with chromobox protein homolog 7, a component 
of the polycomb repressive complex 1 (PRC1), and mediate transcriptional silencing of the 
CDKN2A locus.70 One possible link between ANRIL and T2DM is the tumour suppressor 
p16-INK4a, a 148 amino acid protein encoded in the CDKN2A locus in humans and the 
Cdkn2a (also known as P16ink4a) locus in mice, as the expression of Cdkn2a was observed 
to be upregulated with ageing of the endocrine pancreas in mice, which limited the 
regenerative capacity of β cells.71 ANRIL might contribute to glucose homeostasis by 
maintaining the repressive state of the Cdkn2a locus and thus promoting β-cell division.
Natural antisense to PINK1 (naPINK1), which is expressed in muscle and adipose tissue, has 
also been associated with obesity and T2DM.72 An association of KCNQ1OT1, which is 
expressed in the pancreas,60,73 with T2DM has also been found.67,73 However, the 
functional roles of naPINK1 and KCNQ1OT1 in these diseases, if any, remain to be 
established.
Not much is known about the roles of lncRNAs in the development of type 1 diabetes 
mellitus (T1DM), but genetic studies have identified associations between the imprinted 
DLK1-MEG3 genetic region and T1DM.74 The protective allele of MEG3, a lncRNA, was 
less common among fathers than among mothers of affected offspring.74 Of note, the DLK1-
MEG3 imprinted locus is also implicated in the pathogenesis of nonfunctioning pituitary 
adenomas.75
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Whereas these studies have begun to implicate lncRNAs in the development and physiology 
of β cells and in glucose metabolism, further studies in cell culture and in animal models are 
needed to clarify their roles in these processes and their mechanisms of action.
Adipose tissue function
Two principal types of fat tissue exist in mammals. White adipose tissue (WAT) is 
specialized in storing chemical energy in the form of triglycerides, whereas brown adipose 
tissue (BAT) is specialized in generating heat and consuming energy as a defence against 
cold and obesity.76 Although not primarily known as an endocrine organ, adipose tissue 
secretes about 30 different soluble factors, some of which act as hormones. For instance, 
adipose tissue secretes leptin, which binds to its receptor in the hypothalamus and regulates 
appetite, and adiponectin, which modulates a number of metabolic processes, including 
glucose metabolism and fatty acid oxidation.
In the first description of a role for a non-coding RNA in the development of adipocytes, the 
steroid receptor RNA activator 1 (Sra1) lncRNA was shown to bind to and coactivate 
PPARγ in mice.58 In a follow-up study, the same research group generated mice in which 
the Sra1 locus was deleted.59 These mice were resistant to developing obesity and glucose 
intolerance induced by a high-fat diet and had increased whole-body insulin sensitivity. 
However, whether the observed phenotype reflects an impaired development of adipocytes 
owing to decreased PPARγ function needs to be determined, as the Sra1 knockout might 
also affect organs other than adipose tissue. Moreover, Sra1 might not be an authentic non-
coding RNA, as some isoforms of the Sra1 gene encode a protein called SRAP.77 Knocking 
out Sra1 would have diminished the expression of SRAP and the observed phenotype could 
possibly have been the result of SRAP loss.
Using massively parallel sequencing of polyadenylation-selected RNAs during 
adipogenesis, we identified more than 175 differentially regulated lncRNAs during 
adipogenesis in both WAT and BAT.78 In adipocytes, the promoters of 57 of these 175 
genes were bound by PPARγ and C/EBPα, two major adipogenic transcription factors. 
Furthermore, loss-of-function studies using small interfering RNAs (siRNAs) characterized 
10 lncRNAs that, when suppressed, inhibited the differentiation of adipocytes to different 
extents; we named these lncRNAs regulated in adipogenesis (RAP) 1–10.
We further characterized lncRAP-1 in detail; lncRAP-1 was particularly interesting because 
this lncRNA has a conserved human ortholog on the X chromosome, contains multiple 156 
bp repeating RNA domains and has numerous alternatively spliced isoforms.47 Because of 
these features, lncRAP-1 was renamed functional intergenic repeating RNA element 
(FIRRE). FIRRE is a strictly nuclear lncRNA. It localizes across a 5 Mb domain near its site 
of transcription and is in close proximity to five distinct transchromosomal loci,47 four of 
which were previously described as having regulatory roles in adipogenesis.79-82 RNA-
pulldown assays showed that the heterogeneous nuclear ribonucleoprotein U (hnRNPU) 
binds to FIRRE and that the distinct 156 bp RNA repeats are necessary for this interaction.47 
Importantly, the FIRRE–hnRNPU interaction is needed for colocalization of the 
transchromosomal loci contacted by FIRRE, indicating that this lncRNA is an important 
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nuclear organization factor that brings loci encoding known regulators of adipogenesis into 
close proximity within the nucleus and enables their co-regulation.
A lncRNA named Blnc1 is important for thermogenic differentiation of brown and beige 
adipocytes in mice.83 Blnc1 expression is regulated by the transcription factor COE2 (also 
known as EBF-2). Blnc1, in turn, binds to COE2, which forms a feed-forward loop that 
results in enhanced expression of COE2, as well as enhanced expression of UCP 1 and 
mitochondrial genes, which are important for thermogenesis. Enhancing BAT activity or 
inducing BAT features in WAT have been associated with beneficial metabolic phenotypes, 
and thus are promising therapeutic strategies for metabolic diseases.84
Adrenal gland function
The nuclear receptor steroidogenic factor 1 (SF-1) recruits another nuclear receptor, DAX-1 
(dosage sensitive sex reversal–adrenal hypoplasia congenita critical region on the X 
chromosome protein 1, also known as nuclear receptor subfamily 0 group B member 1) to 
the promoter of the gene that encodes the adrenocorticotropic hormone receptor (also known 
as MC2-R), which induces transcription of this gene. Transcriptional activation of MC2R is 
dependent on the lncRNA SRA1, as knockdown of SRA1 in human JEG-3 and Y1 cells 
(placental and adrenal cell lines, respectively) reduced the expression of MC2R.85 These 
results suggest that SRA1 plays an important part in adrenal gland function and sex 
determination.
Mammary gland function
The expansion and regression of the mammary gland during pregnancy is regulated by 
hormones, including estrogens and progesterone. In a screen for persistently upregulated 
RNAs after estrogen and progesterone treatment in rats, the lncRNA Gb7 was identified.86 
This lncRNA was then renamed pregnancy-induced non- coding RNA (Pinc). Homology 
searches in different species revealed several conserved homologs in mammals but not in 
fugu (pufferfish), zebrafish or Xenopus genomes.87 In mouse, the expression of two splice 
variants, mPinc1.0 and mPinc1.6, increases in lobuloalveolar structures of the mammary 
gland during pregnancy, drops during lactation and rises again at day 5 of involution, which 
suggests that mPinc prevents alveolar differentiation before parturition.87 Knockdown of 
mPinc1.0 promoted apoptotic cell death, whereas knockdown of mPinc1.6 facilitated the 
G1–S phase transition, and knockdown of both lncRNAs resulted in enhanced lactogenic 
differentiation. On the other hand, overexpression of mPinc1.0 inhibited activation of 
alveolar cells to produce and secrete milk proteins.88 RNA immunoprecipitation 
experiments revealed that mPinc binds to polycomb repressive complex 2 (PRC2), which 
suggests that mPinc facilitates the maintenance of a repressive chromatin state.88 In a similar 
manner, the mouse zinc finger antisense 1 (Zfas1) lncRNA was characterized as 
downregulated between pregnancy and lactation, and upregulated between lactation and 
involution.89 Of note, knockdown of Zfas1 promoted proliferation and differentiation, which 
suggests Zfas1 acts as a tumour suppressor. This hypothesis was further substantiated by the 
observation that the human ortholog ZFAS1 is downregulated in invasive ductal carcinoma 
tissue compared with normal breast tissue.89
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Regulation of circadian rhythms
The pineal gland is an important endocrine organ that controls circadian periodicity of gene 
expression, mainly by the production of melatonin at night. In a search for lncRNAs whose 
expression oscillates throughout the day, a group of researchers analysed RNA expression 
profiles in the rat pineal gland. The group identified 112 lncRNAs that were differentially 
expressed during day and night, which were named lncSNs (lncRNAs, Section on 
Neuroendocrinology), with 59% of them having their expression increased during the 
night.90 Eight of these lnSNs, whose size ranged from <1 kb to >50 kb, were chosen for 
further analysis. The rhythmic oscillation of their expression depended on the 
suprachiasmatic nucleus (SCN)–pineal pathway, as this rhythmic oscillation was blocked 
after surgical removal of the SCN but not when the rats were housed in constant darkness.90 
The precise mechanisms and effects of these lncRNAs on circadian rhythm systems needs to 
be further addressed.
Endocrine cancer
LncRNAs have been associated with several endocrine cancers, including breast, prostate, 
ovarian and thyroid cancers, as well as nonfunctioning pituitary tumours. The involvement 
of several lncRNAs in the estrogen and androgen signalling pathways underlies at least part 
of their role in breast and prostate cancers. Many other lncRNAs have also been implicated 
in these two types of endocrine cancers, although whether they affect any nuclear receptor 
pathway remains unknown. More work is needed to identify lncRNAs and annotate their 
function in these and other endocrine cancers, which might reveal new therapeutic targets.
Breast cancer—A global run-on and sequencing study performed in MCF-7 cells, a 
human breast cancer cell line, revealed a rapid, robust and transient induction of a large 
fraction of genes immediately after estrogen treatment, including many lncRNAs as well as 
other types of non-coding transcripts.91 A large number of previously undetected lncRNA 
transcripts was found in enhancer regions and intergenic regions proximal to estrogen-
receptor binding sites, which suggests these transcripts have a role in the estrogen-dependent 
transcriptional response. In another study in the MCF-7 cell line, stimulation of the estrogen 
receptor by 17β-estradiol increased global transcription of enhancer lncRNAs near estrogen-
activated coding genes.92 Knocking down a set of enhancer lncRNAs using siRNAs 
attenuated the expression of target genes. Furthermore, using a three-dimensional DNA 
selection and ligation assay, the researchers showed that blocking enhancer lncRNA 
expression could destabilize 17β-estradiol-induced promoter–enhancer interactions, at least 
at one of the 17β-estradiol targets, the Nrip1 locus.92 These findings show that enhancer 
lncRNA expression is functionally important for estrogen-dependent transcription 
activation.
The lncRNA HOTAIR is upregulated by estradiol binding to estrogen receptors ERα and 
ERβ. Co-regulators including histone methyltransferases MLL1 and MLL3 and histone 
acetylases of the p300–CBP family are recruited together with estrogen receptors to bind 
estrogen response elements in the HOTAIR promoter in response to 17β-estradiol treatment 
and are necessary for the upregulation of HOTAIR.93 HOTAIR was highly expressed in 
metastatic breast cancers with poor survival outcomes.23 Enforced expression of HOTAIR in 
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epithelial cancer cells drives a genome-wide shift of the binding pattern of PRC2 towards a 
pattern that is typically seen in embryonic fibroblasts, which is associated with a PRC2-
dependent alteration in gene expression and increased cancer invasiveness. Conversely, 
siRNA-induced loss of HOTAIR expression decreased matrix invasiveness in the MCF-7 
cell line.23 Thus, HOTAIR is of functional importance for the progression of estrogen-
supported breast cancers.
One of the best studied lncRNAs that interacts with the estrogen receptor is SRA1. SRA1 
functions as a nuclear receptor corepressor in estrogen signalling by binding to SHARP-194 
and SLIRP,95 two general corepressors of nuclear receptor signalling. SRA1 associates with 
NCoA-1 (also known as SRC-1) upon estrogen induction, which leads to activation of 
estrogen-induced gene transcription. Estrogen signalling then induces expression of the 
corepressor SHARP-1, which, together with SLIRP, competes for the binding of SRA1 and 
NCoA-1. This competition leads to repression of estrogen-induced genes, which is a 
possible regulatory mechanism whereby estrogen hormone responses are attenuated.
Long stress-induced non-coding RNAs (LSINCTs) are highly expressed in breast cancers 
and were initially identified in a screen for genes that respond to the tobacco carcinogen 
nicotine-derived nitrosamine ketone.96 In a follow-up study, LSINCT5 was found to be 
overexpressed in most breast and ovarian cancer cell lines, and knockdown of this lncRNA 
resulted in decreased cell proliferation.97
Prostate cancer—Two lncRNAs, PCGEM1 and PRNCR1,98,99bind sequentially to the 
androgen receptor and strongly enhance both ligand-dependent and ligand-independent gene 
activation in prostate cancer cells.100 Binding of PRNCR1 is required for the recruitment of 
PCGEM1 to the androgen receptor. Each of these lncRNAs serves as a scaffold and forms a 
complex with a distinct set of proteins that enhances the looping of androgen-receptor-
bound enhancers to target gene promoters, a mechanism similar to that observed in the 
enhancer lncRNAs interacting with the estrogen receptor.92 Interestingly, the expression of 
PCGEM1 and PRNCR1 is highly increased in aggressive prostate cancer, as well as 
castration- resistant prostate cancer cell lines. In castration- resistant prostate cancer cells, 
these overexpressed lncRNAs, through direct interactions with the androgen receptor, are 
required for ligand-independent activation of the androgen receptor and cell proliferation.100 
Together, these data show that lncRNAs are required components of the regulatory network 
downstream of the androgen receptor.
In another study, 121 lncRNAs that were not annotated in the UCSC, Ensembl, Refseq, 
Vega or Encode genome databases as prostate-cancer-associated lncRNA transcripts 
(PCATs) were identified in a cohort of 102 prostate tissue specimens and cell lines.101 
PCAT1 was specifically overexpressed in a subset of metastatic prostate cancers and 
functions as a transcriptional repressor in a complex with PRC2, which leads to the 
inhibition of some tumour-suppressor factors such as BRCA2, CENPE and CENPF, and the 
enhancement of cell proliferation.101
The androgen-responsive lncRNA CTBP1-AS was identified in a screen of androgen-
sensitive prostate adenocarcinoma cells (LNCaP cells).102,103 CTBP1-AS is transcribed in 
Knoll et al. Page 9
Nat Rev Endocrinol. Author manuscript; available in PMC 2015 March 27.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
antisense to the gene encoding CTBP1, a corepressor of androgen receptor signalling, and 
represses the expression of CTBP1, thereby promoting androgen-receptor signalling. These 
observations suggest CTBP1 has a role in the development of androgen-dependent and 
castration-resistant prostate cancers.103
Other endocrine cancers—The lncRNA MEG3 is implicated in the pathogenesis of 
nonfunctioning pituitary adenomas. MEG3 is expressed in normal pituitary cells but this 
expression is lost in non-functioning pituitary adenomas;75 this lncRNA has been proposed 
to act as a tumour suppressor.104 PTCSC3 was identified in a GWAS of papillary thyroid 
cancer.105,106 The expression of PTCSC3107 and that of NAMA and AK023948108,109 were 
found to be downregulated in thyroid cancer, but the contributions of these lncRNAs to 
thyroid cancer remain unclear.
Response to starvation
Induced expression of the lncRNA GAS5 represents a response to insufficient nutrient 
supply states, such as starvation and cell growth arrest.110 In these states, upregulated GAS5 
binds the DNA-binding domain of the glucocorticoid receptor, thereby decoying the 
receptor away from its glucocorticoid response element targets in genomic DNA and 
inhibiting transcriptional responses to glucocorticoids.110
Conclusions and perspectives
On the basis of the pioneering studies reviewed above, several conclusions can be safely 
drawn. First, as in other cell types, lncRNAs have critical roles in the development of 
endocrine cells. Second, the regulated expression of many lncRNAs in response to 
hormones is required for these hormones to exert their full functions in target cells, 
including cells with aberrant functions such as cancer cells. Third, some SNPs in lncRNA 
loci have been linked with endocrine diseases as well as some endocrine cancers.
Our understanding of lncRNAs in the endocrine system is still at its infancy and many 
questions remain unanswered. First, because many lncRNAs are expressed in a cell-type-
specific manner, currently annotated databases of lncRNAs that are based on previous RNA 
sequencing studies are likely to be incomplete or inaccurate for some cell types. This 
problem might be particularly important for the endocrine system, because many endocrine 
organs are composed of very specialized cell types that are likely to express functional 
lncRNAs that are unique to that cell type. Discovery and annotation of lncRNAs in these 
cell types remains important for future work. As shown by pioneering studies in this area,60 
obtaining pure populations of different cell types and conducting in-depth RNA sequencing 
on both polyadenylated RNAs and non-polyadenylated RNAs that have been depleted of 
rRNAs is an essential first step, followed by detailed bioinformatic analysis to identify a 
comprehensive list of lncRNAs that is enriched in particular cell types.8,33
Second, the biological functions of lncRNAs in the endocrine system are still poorly 
understood. This problem will require developing genetic models to fully assess the role of 
lncRNAs on a variety of homeostatic processes in vivo. In addition, a large number of 
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associations between endocrine diseases and SNPs affecting lncRNA expression have been 
established, but their cause–effect relationship should be carefully evaluated.
Third, we need to gain deeper insight into the molecular mechanisms used by lncRNAs to 
regulate gene expression. Numerous new techniques, developed to dissect the complicated 
interactions between RNA, proteins, and chromatin—including crosslinking 
immunoprecipitation, RNA antisense purification, chromatin isolation by RNA purification, 
capture–hybridization analysis of RNA targets and chromatin oligoaffinity precipitation—
offer unprecedented opportunities to perform detailed mechanistic studies in the near future.
Fourth, a need exists to identify and classify the secondary and tertiary structures of 
lncRNAs according to their functions. Several dimethyl-sulphate-based methods have been 
developed for genome-wide profiling of the secondary structures of RNAs.111–113 The 
development of such methods might enable classification of lncRNA families on the basis of 
structural domains in ways similar to classification of protein families on the basis of 
structural domains.
Finally, lncRNAs can be potentially developed as novel diagnostic markers. For example, 
the expression levels of HOTAIR in primary breast tumours are powerful predictors of 
eventual metastasis and death.23 Several other lncRNAs have also been proposed as markers 
for endocrine malignancy.114 However, the sensitivity and reliability of these markers still 
need to be rigorously evaluated.
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Key points
• A substantial proportion of the genome is transcribed into non-coding RNAs, 
including many long non-coding RNAs (lncRNAs) that are important regulators 
of endocrine cells
• Many research findings point towards an important role of lncRNAs in 
regulating the development and maintenance of endocrine organs and hormonal 
signalling; misregulation of these processes can lead to disease
• The biological functions of lncRNAs in endocrine organs are poorly understood; 
genetic models are needed to fully assess the role of lncRNAs in a variety of 
homeostatic processes in vivo
• lncRNAs can be potentially developed as novel diagnostic markers to identify 
and classify certain tumours
Knoll et al. Page 17
Nat Rev Endocrinol. Author manuscript; available in PMC 2015 March 27.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Review criteria
The PubMed search engine was used to identify articles relevant to the topic published 
from 1999 to September 2014. The following search terms were used: “long non-coding 
RNA”, “long non-coding RNAs endocrine”, “long non-coding RNAs cancer”, “long non-
coding RNAs development”, “long non-coding RNAs nuclear receptors”, “long non-
coding RNAs pancreas”, “long non-coding RNAs adipocytes”. Every search was done 
twice, using the filter “review” or not. Only full-text papers, reviews and resource articles 
in English were included. The lists of references of cited papers were searched for 
articles important for this Review and published before 1999. The authors regret that 
owing to space limitations not every relevant article could be cited.
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Figure 1. 
Categories of long non-coding RNAs classified on the basis of their genomic region.
Knoll et al. Page 19
Nat Rev Endocrinol. Author manuscript; available in PMC 2015 March 27.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 2. 
Mechanisms of lncRNA action. Most lncRNAs are nuclear and their most common 
mechanism of action is via recruitment of chromatin modifiers to DNA. These chromatin 
modifiers can be repressive (such as the PRC1/2 or the LSD1–CoREST complexes), 
activating (such as transcriptional mediators or the WDR5–MLL complex) or other 
modifiers such as hnRNPs as nuclear organization factors. Some lncRNAs bind to specific 
proteins and act as scaffolds within ribonucleoprotein complexes. In the cytosol, circular or 
linear lncRNAs can act at the post-transcriptional level as sponges for miRNAs, therefore 
inhibiting the actions of miRNAs on mRNAs. A few examples of lncRNAs that affect the 
half-life of mRNAs by either destabilizing or stabilizing a specific subset of mRNAs have 
been described. Abbreviations: hnRNP, heterogeneous ribonucleoprotein; lncRNA, long 
non-coding RNA; miRNA, microRNA; PRC, polycomb repressor complex.
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Figure 3. 
Endocrine organs and lncRNAs. lncRNAs known to be involved in the development, 
physiology and/or disease of each endocrine organ are indicated in the image. lncRNAs 
highlighted in bold grey are involved in cancer.
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Table 1
lncRNAs in endocrine organs
Endocrine organ lncRNA Association with disease Physiological function Study
Hypothalamus Unknown names Unknown Unknown Roy et al.115
Pineal gland lncSN family Unknown Circadian rhythm regulation Coon et al.90
Pituitary gland MEG3 Pituitary adenomas Unknown Cheunsuchon et al.75; 
Zhou et al.104
Thyroid gland PTCSC3 Thyroid cancer Competing endogenous RNA for 
microRNAs
Gudmundsson et 
al.105,106; Jendrzejewski et 
al.107
NAMA Thyroid cancer Unknown Yoon et al.108
AK023948 Thyroid cancer Unknown He et al.109
Mammary gland mPinc1.0, mPinc1.6 Unknown Prevents alveolar differentiation Ginger et al.87; Shore et 
al.88
Zfas1 Mammary cancer Unknown Askarian-Amiri et al.89
HOTAIR Mammary cancer Unknown Bhan et al.93
LSINCT5 Mammary cancer Proliferation Silva et al.96; Silva et 
al.97
Pancreas HI-LNC25 T2DM Positively regulates GLIS3 mRNA 
levels
Morán et al.60
HOTAIR Pancreatic cancer Enhances cell invasion Kim et al.116
ANRIL T2DM In mouse, controls expression of 
Cdkn2a (also known as P16ink4a)
Krishnamurthy et al.71
KCNQ1OT1 T2DM Unknown Voight et al.73
H19 T2DM Unknown Ding et al.65
Adrenal gland SRA1 Unknown Coactivator of steroidogenesis Xu et al.85
Adipose tissue lncRAP family, including Unknown Promotes adipogenesis Sun et al.78
FIRRE Unknown Promotes adipogenesis by binding 
hnRNPU
Hacisuleyman et al.47
Sra1 Unknown Promotes adipogenesis by binding 
PPARγ
Xu et al.117; Liu et al.118
Blnc1 Unknown Thermogenic differentiation Zhao et al.83
naPINK1 T2DM Suppressor of PINK1 Scheele et al.72
Ovary LSINCT5 Ovarian cancer Stimulates proliferation Silva et al.96
Testes Unknown names Unknown Unknown Sun et al.119
Prostate gland PCAT1 Prostate cancer Transcriptional repressor Prensner et al.101
PRNCR1, PCGEM1 Prostate cancer Ligand-independent activation of 
the androgen receptor
Chung et al.99; Yang et 
al.100; Li et al.120
CTBP1-AS Prostate cancer Represses CTBP1 expression Takayama et al.103
ANRIL Prostate cancer Tumour suppressor Yap et al.70
Abbreviations: hnRNPU, heterogeneous nuclear ribonucleoprotein U; lncRNA, long non-coding RNA; T2DM, type 2 diabetes mellitus.
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